PD 146176
Latest Information Update: 19 Jul 2000
At a glance
- Originator Pfizer
- Class Fluorenes
- Mechanism of Action Lipoxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atherosclerosis
Most Recent Events
- 19 Jul 2000 No-Development-Reported for Atherosclerosis in USA (Unknown route)
- 21 Jun 2000 Warner-Lambert has merged with Pfizer
- 22 May 1998 New profile